



FOR IMMEDIATE RELEASE

Contact:
Lynda Sutton
President
Cancer Advances, Inc.
Phone: 919-361-2162
email: info@canceradvancesinc.com
www.canceradvancesinc.com

Cancer Advances Announces Allowance of a New Patent to Its Suite of Gastrin Inhibitor Products

Durham, NC, July 15, 2013 — Cancer Advances, Inc. (Cancer Advances), a wholly owned, biotechnology portfolio company of [Cato BioVentures](#), announces the allowance of a new patent. The newly released patent covers monoclonal antibodies to the gastrin hormone and has been allowed in Canada. This patent is an additive to Cancer Advances' suite of products that work to inhibit the cancer promoting hormone, gastrin.

Cancer Advances has developed an intellectual property portfolio that currently holds over 100 United States and worldwide patents related to a lead compound, Polyclonal Antibody Stimulator (PAS) that has been clinically studied in three gastrointestinal cancers. PAS is an active immunotherapeutic that induces antibodies against the hormone, gastrin 17 (G17), and its precursor, (gly)G17, of which there is extensive published evidence for a central role of both of these endogenous compounds in the development and progression of gastrointestinal tumors, as well as other tumors.

The monoclonal antibodies to gastrin hormone patent cover a pharmaceutical composition, comprised of a humanized monoclonal antibody to gastrin. This patent also covers a method of diagnosing, preventing or treating a gastrin-mediated disease or condition. Combined with Cancer Advances' already extensive arsenal of patents, this newly allowed patent will help in the fight against gastrin-mediated diseases.

Cancer
Advances is
DEDICATED
to enhancing
the immune system
and augmenting
human quality of life by
targeting the progression
of gastrointestinal cancers.

Cancer Advances
P | 919-361-2162
E | info@canceradvancesinc.com
www.canceradvancesinc.com



For more information, please contact:

Lynda Sutton

President, Cancer Advances

lsutton@cato.com

919-361-2162

www.canceradvancesinc.com

About Cancer Advances

Cancer Advances is a biotechnology company focused on impacting human health and suppressing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio.

Please visit our product page for more information on what is in development:

<http://www.canceradvancesinc.com/product.html>

###

Cancer
Advances is
DEDICATED
to enhancing
the immune system
and augmenting
human quality of life by
targeting the progression
of gastrointestinal cancers.

Cancer Advances

P | 919-361-2162

E | info@canceradvancesinc.com

www.canceradvancesinc.com